β-substituted cyclohexanecarboxamide: A nonpeptidic framework for the design of potent inhibitors of cathepsin K

Journal of Medicinal Chemistry

Volumn 49, Issue 3, 2006, Pages 1066-1079

  Crane, Sheldon N ^a   Black, W Cameron ^b   Palmer, James T ^b   Davis, Dana E ^b   Setti, Eduardo ^b   Robichaud, Joel ^a   Paquet, Julie ^a   Oballa, Renata M ^a   Bayly, Christopher I ^a   McKay, Daniel J ^a   Somoza, John R ^b   Chauret, Natalie ^a   Seto, Carmai ^a   Scheigetz, John ^a   Wesolowski, Greg ^c   Massé, Frederic ^a   Desmarais, Sylvie ^a   Quellet, Marc ^a  

^a MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

^b CELERA   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATHEPSIN B; CATHEPSIN K INHIBITOR; CATHEPSIN L; CATHEPSIN S; CYCLOHEXANE DERIVATIVE; CYCLOHEXANECARBOXAMIDE DERIVATIVE; N (CYANOMETHYL) 2 [(4 BROMOPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(4 CHLOROPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(4 FLUOROPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(4 HYDROXYPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(4 IODOPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(4 METHOXYPHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [(PHENYLTHIO)METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [[(3 FLUOROPHENYL)THIO]METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 2 [[4 (METHYLTHIO)PHENYLTHIO]METHYL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 5 FLUORO 2 [4' (METHYLTHIO)BIPHENYL 2 YL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 5,5 DICHLORO [4' (METHYLTHIO) 1,1' BIPHENYL 2 YL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 5,5 DIFLUORO 2 [4' FLUOROBIPHENYL 2 YL]CYCLOHEXANECARBOXAMIDE; N (CYANOMETHYL) 5,5 DIFLUORO [4' (METHYLTHIO) 1,1' BIPHENYL 2 YL]CYCLOHEXANECARBOXAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HALF LIFE TIME; MALE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; RAT; STRUCTURE ACTIVITY RELATION;

AMIDES; AMINOACETONITRILE; ANIMALS; BIOLOGICAL AVAILABILITY; CATHEPSINS; CRYSTALLOGRAPHY, X-RAY; CYCLOHEXANES; DOGS; HALF-LIFE; MALE; MODELS, MOLECULAR; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 32344432987     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm051059p     Document Type: Article

References (27)

1. (a) Bromme, D.; Okamoto, K.; Wang, B. B.; Biroc, S. Human Cathepsin O2, a Matrix Protein-Degrading Cysteine Protease Expressed in Osteoclasts. J. Biol. Chem. 1996, 271, 2126-32.
2. (b) Bossard, M. J.; Tomaszek, T. A.; Thompson, S. K.; Amegadzie, B. Y.; Hanning, C. R.; Jones, C.; Kurdyla, J. T.; McNulty, D. E.; Drake, F. H.; Gowen, M.; Levy, M. A. Proteolytic Activity of Human Osteoclast Cathepsin K. Expression, Purification, Activation, and Substrate Identification. J. Biol. Chem. 1996, 271, 12517-24.
3. (c) Tezuka, K.; Tezuka, Y.; Maejima, A.; Sato, T.; Nemoto, K.; Kamioka, H.; Hakeda, Y.; Kumegawa, M. Molecular Cloning of a Possible Cysteine Proteinase Predominantly Expressed in Osteoclasts. J. Biol. Chem. 1994, 269, 1106-9.
4. (d) Turk, B.; Turk, D.; Turk, V. Lysosomal Cysteine Proteases: More than Scavengers. Biochim. Biophys. Acta 2000, 1477, 98-111.
5. (e) Drake, F. H.; Dodds, R. A.; James, I. E.; Connor, J. R.; Debouck, C.; Richardson, S.; Lee-Rykaczewski, E.; Coleman, L.; Rieman, D.; Barthlow, R.; Hastings, G.; Gowen, M. Cathepsin K, but not Cathepsin B, L, or S, Is Abundantly Expressed in Human Osteoclasts. J. Biol. Chem. 1996, 271, 12511-16.
6. (f) Troen, B. R. The Role of Cathepsin K in Normal Bone Resorption. Drug News Perspect. 2004, 17, 19-28.
7. (a) Peck, W. A.; Burckhardt, P.; Christiansen, C.; Fleisch, H. A.; Genant, H. K.; Gennari, C.; Martin, T. J.; Martini, L.; Morita, R.; Ogata, E.; Rapado, A.; Shulman, L. E.; Stern, P. H.; Young, R. T. T.; Barrett-Connor, E.; Brandi, M. L.; Chesnut, C. H.; Delmas, P. D.; Heaney, R. P.; Johnston, C. C.; Kanis, J. A.; Lindsay, R.; Meunier, P. J.; Papapoulos, S. E.; Reginster, J. Y.; Riggs, B. L.; Riis, B. J.; Seeman, E.; Wasnich, R. D. Consensus Development Conference: Diagnosis, Prophylaxis and Treatment of Osteoporosis. Am. J. Med. 1993, 94, 646-50.
8. (b) Blair, H. C.; Athanasou, N. A. Recent Advances in Osteoclast Biology and Pathological Bone Resorption. Histol. Histopathol. 2004, 19, 189-99.
9. (a) Suzue, S.; Irikura, T. Studies on Hepatic Agents. I. Synthesis of Aminoacyl (and Hydroxyacyl) Aminoacetonitriles. Chem. Pharm. Bull. 1968, 16, 1417-32.
10. (b) Bryant, C. M.; Palmer, J. T.; Rydzewski, R. M.; Setti, E. L.; Tian, Z.-Q.; Venkatraman, S.; Wang, D.-X. Preparation of Novel N-Cyanomethylamide Compounds and Compositions as Protease Inhibitors. World Patent 2000/55126. Chem. Abstr. 2000, 133, 252050.
11. (a) Robichaud, J.; Oballa, R.; Prasit, P.; Falgueyret, J.-P.; Percival, M. D.; Wesolowski, G.; Rodan, S. B.; Kimmel, D.; Johnson, C.; Bryant, C.; Venkatraman, S.; Setti, E.; Mendonca, R.; Palmer, J. T. A Novel Class of Nonpeptidic Biaryl Inhibitors of Human Cathepsin K. J. Med. Chem. 2003, 46, 3709-37.
12. (b) Falgueyret, J.-P.; Oballa, R.; Okamoto, O.; Wesolowski, G.; Aubin, Y.; Rydzewski, R. M.; Prasit, P.; Riendeau, D.; Rodan, S. B.; Percival, M. D. Novel, Nonpeptidic Cyanamides as Potent and Reversible Inhibitors of Human Cathepsins K and L. J. Med. Chem. 2001, 44, 94-104.
13. 3 Benzamide-Containing Aminonitriles as Potent, Selective, Orally Effective Inhibitors of Cathepsin K. J. Med. Chem. 2005, 48, 7520-34.
14. (b) Falgueyret, J.-P.; Desmarais, S.; Oballa, R.; Black, W. C.; Cromlish, W.; Khougaz, K.; Lamontagne, S.; Massé, F.; Riendeau, D.; Toulmond, S.; Percival, M. D. Lysosomotropism of Basic Cathepsin K Inhibitors Contributes to Increased Cellular Potencies Against off-target Cathepsins and Reduced Functional Selectivity. J. Med. Chem. 2005, 48, 7535-43.
15. 157).
16. See ref 4a for expression and purification procedures. Cyclohexanecarboxamide-based inhibitors were equipotent against humanized-rabbit and human Cat K.
17. Condon, M. E.; Petrillo, E. W., Jr.; Ryono, D. E.; Reid, J. A.; Neubeck, R.; Puar, M.; Heikes, J. E.; Sabo, E. F.; Losee, K. A.; Cushman, D. W.; Ondetti, M. A. Angiotensin-Converting Enzyme Inhibitors: Importance of the Amide Carbonyl of Mercaptoacyl Amino Acids for Hydrogen Bonding to the Enzyme. J. Med. Chem. 1982, 25, 250-58.
18. Case, D. A.; Pearlman, D. A.; Caldwell, J. W.; Cheatham, T. E., III; Ross, W. S.; Simmerling, C. L.; Darden, T. A.; Merz, K. M.; Stanton, R. V.; Cheng, A. L.; Vincent, J. J.; Crowley, M.; Tsui, V.; Radmer, R. J.; Duan, Y.; Pitera, J.; Massova, I.; Seibel, G. L.; Singh, U. C.; Weiner, P. K.; Kollman, P. A. AMBER 6; University of California, San Francisco, 1999. Molecular dynamics calculations were carried out using explicit water in a periodic box under nvt conditions (constant number of molecules, volume, and temperature).
19. (a) Miyashita, K.; Tanaka, A.; Mizuno, H.; Tanaka, M.; Iwata, C. Dimethyl Sulfoxide-Trimethylsilyl Bromide-Amine System as a Bromonium Ion Source Containing a Potential Internal Nucleophile; Unusual Bromolactonization of Cyclohex-3-enecarboxylic Acid Derivatives. J. Chem. Soc., Perkin Trans. I 1994, 847-51. The structure assigned to 29 was corroborated by COSY, HMBC, and HSQC 2-D NMR experiments.
20. (b) Markovskij, L. N.; Pashinnik, V. E.; Kirsanov, A. V. Application of Dialkylaminosulfur Trifluorides in the Synthesis of Fluoroorganic Compounds. Synthesis 1973, 787-9.
21. In general, P3 SAR trends were not influenced by the nature of the P2-P3 linker or the presence of fluorine substituents on the cyclohexyl ring.
22. Verbit, L.; Price, H. C. Optically Active Aromatic Chromphores. XI. Circular Dichroism Studies of Some 1-Substituted 2-Phenylcyclohexanes. J. Am. Chem. Soc. 1972, 94, 5143-52.
23. This corresponds with the absolute stereochemistry determined for 13e and also with the more potent enantiomer of 12f prepared from (+)-(1R,2R)-9 (purchased from TCI organic chemicals, cat no C1417).
24. 2, see: Schmidt, S. E.; Salvatore, R. N.; Jung, K. W.; Kwon, T. Efficient Synthesis of Cyclopropylacetylene, a Crucial Synthetic Intermediate for Efavirenz (DMP-266). Synlett 1999, 1948-50.
25. Coupling constant analysis for the proton attached to the fluorine bearing carbon was used to assign the fluorine orientations on the conformationally biased cyclohexyl ring. The reactions of 36a and 36b with DAST proceeded with inversion at the alcohol bearing stereocenter.
26. Falgueyret, J.-P.; Black, W. C.; Cromlish, W.; Desmarais, S.; Lamontagne, S.; Mellon, C.; Riendeau, D.; Rodan, S.; Tawa, P.; Wesolowski, G.; Bass, K. E.; Venkatraman, S.; Percival, D. An Activity Based Probe for the Determination of Cysteine Cathepsin Protease Activities in Whole Cells. Anal. Biochem. 2004, 335, 218-27.
27. McGrath, M. E.; Sprengeler, P. A.; Hill, C. M.; Martichonok, V.; Cheung, H.; Somoza, J. R.; Palmer, J. T.; Jane, J. W. Peptide Ketobenzoxazole Inhibitors Bound to Cathepsin K. Biochemistry 2003, 42, 15018-28.